Descrizione del progetto
L’approccio della medicina di precisione al trattamento della sepsi
La sepsi, la risposta estrema del corpo a un’infezione esistente, è un’emergenza medica potenzialmente letale. Senza un trattamento urgente, la sepsi può condurre rapidamente a danno tissutale, insufficienza d’organo e morte. Gli antibiotici e le unità di terapia intensiva hanno drasticamente migliorato il trattamento della sepsi, e si spera che l’immunoterapia possa ulteriormente perfezionarne gli esiti. La missione del progetto ImmunoSep, finanziato dall’UE, è quella di progettare e completare una sperimentazione clinica di prova di concetto sull’immunoterapia personalizzata nella sepsi e sviluppare una piattaforma di teranostica di nuova generazione per future sperimentazioni sull’immunoterapia personalizzata nella sepsi. La teranostica è un nuovo approccio che combina una terapia bersaglio specifica a diagnostica mirata specifica. La piattaforma di teranostica del progetto attuale sarà basata su un’analisi biologica dei sistemi multidimensionali per set di dati basati sull’omica al fine di identificare i biomarcatori clinicamente pertinenti e i bersagli terapeutici per la medicina di precisione.
Obiettivo
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, and is characterized by a high mortality of up to 30-40%. Treatment of sepsis was revolutionized by two steps that significantly decreased mortality: antibiotics and the intensive care units. It has been hoped that a third revolution, immunotherapy, would further improve outcome of sepsis, but this hope did not materialize. This was due to the incompletely understood pathophysiology, and the heterogeneity of the immune status in different sepsis patients. We propose that while both overinflammation and immunoparalysis are important, they are present in individual sepsis patients.The mission of the present project is to design and perform a proof-of-concept clinical trial of personalized immunotherapy in sepsis, and within this clinical trial, to develop a next-generation theranostics platform for the design of future personalized immunotherapy trials in sepsis. This theranostics platform would be based on an integrated, multidimensional systems biology analysis of omics-based datasets, to identify biomarkers, clinical endotypes, and therapeutic targets for precision medicine approaches. In order to achieve the mission proposed, several complementary aims will be pursued: Aim 1: To design and perform a large personalized immunotherapy trial in sepsis patients, that can provide a clinical answer towards the usefulness of currently employed immunotherapies for sepsis. Aim 2: To chart host genome, epigenome, transcriptome, metabolome and microbiome in at least 180 sepsis patients enrolled in Aim 1 over a defined time course. Aim 3: To use a theranostics approach based on the data provided by Aim 2 to design novel personalized immunotherapeutic strategies. Aim 4: To integrate the clinical and psychological aspects involved when introducing novel immunotherapies for infections in the health care systems of European countries, building bridges with the patient community.
Campo scientifico
- social sciencessociologydemographymortality
- medical and health sciencesclinical medicinecritical care medicine
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-2019-Two-Stage-RTD
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
6525 GA Nijmegen
Paesi Bassi